NCT06498518 2025-07-11
PRIMUS006
University of Glasgow
Phase 2 Withdrawn
Clinical Trials
5 trialsNCT05431582 2023-06-15
Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT03891979 2020-06-26
Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma
NYU Langone Health
Phase 4 Withdrawn
NCT04058964 2020-03-13
Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT03432676 2019-05-30
Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn